2019 Conference on Retroviruses and Opportunistic Infections*

March 4-7, 2019; Seattle, Washington
Get up to date on the latest HIV data with rapid Capsule Summaries, downloadable slidesets, and expert analysis covering key studies from Seattle.

Highlights From CROI

Capsule Summary Slidesets

Daily oral PrEP with FTC/TAF is noninferior to FTC/TDF in preventing HIV infection in cis-MSM and transgender women at high risk for HIV acquisition.

Released: March 11, 2019

Among individuals recently diagnosed with HIV, those who received PrEP prior to diagnosis were more likely to harbor emtricitabine resistance mutations and to be diagnosed with acute HIV infection vs never-users of PrEP.

Released: March 11, 2019

Switch to long-acting dual therapy regimen maintains virologic suppression at Week 48.

Released: March 9, 2019

Higher patient-reported satisfaction with monthly injectable dual regimen compared with daily oral tablets.

Released: March 11, 2019

In this post-hoc analysis of HIV-infected adults previously failing first-line therapy with NNRTI + 2 NRTIs, HIV-1 RNA < 50 copies/mL was achieved in 82% of DTG recipients with baseline M184V/I and second-line use of 3TC or FTC.

Released: March 13, 2019

Although the overall death rate decreased by 13% from 2011-2015 among HIV-infected individuals, a 43% increase in opioid overdose deaths among the US HIV population was reported.

Released: March 11, 2019

Post hoc analysis finds no evidence of association between cabotegravir use and weight gain.

Released: March 11, 2019

First large randomized study of raltegravir vs efavirenz in pregnant women finds improved virologic suppression at delivery in women receiving raltegravir, particularly when initiating ART after 28 weeks of gestation.

Released: March 7, 2019

In pregnant women with HIV infection who initiated third trimester ART, HIV-1 RNA < 50 copies/mL at delivery achieved in 74% with DTG-based therapy vs 43% with EFV-based therapy.

Released: March 8, 2019

No drug-related serious adverse events and PK exposures comparable to adults with single-tablet regimen BIC/FTC/TAF in patients 6 to < 18 years of age.

Released: March 11, 2019
Directly provided by the Annenberg Center for Health Sciences at Eisenhower
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This program is supported by independent educational grants from
Gilead Sciences
Janssen Therapeutics
Merck & Co., Inc.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?